+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025

  • ID: 5018691
  • Report
  • April 2020
  • Region: Global
  • 233 Pages
  • Arizton
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now
The Epinephrine Auto-Injector Market is Expected to Grow at a CAGR of Over 8% During the Period 2019–2025.

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • ALK-Abelló
  • Amneal Pharmaceuticals
  • Bausch & Lomb
  • Bioprojet PHARMA
  • kaléo
  • MORE

The global epinephrine auto-injector market is expected to grow at a steady rate during the forecast period. The growth can be mainly attributed to the growing prevalence of anaphylaxis across demographics. Anaphylaxis is characterized as a potentially life-threatening systemic allergic reaction, which is most commonly triggered by medication, food allergies, or insect stings. In developed countries such as the US and the UK, the incidence of anaphylaxis is 40–500 per million persons. Anaphylaxis-associated mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. Over the last several years, a rising number of clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are the most commonly prevalent in industrially developed countries such as the US and the UK. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it the first-aid treatment option, thereby driving the global market.

The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period:

  • Emergence of Innovative Solutions for Anaphylaxis Management
  • Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores
  • Growing Demand for Self-administration of Drugs
  • Availability of Generic Versions of Auto-injectors

The study considers the present scenario of the epinephrine auto-injector market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent companies operating in the market.

EPINEPHRINE AUTO-INJECTOR MARKET: SEGMENTATION

This research report includes a detailed segmentation by dosage, age group, end-user, and geography. The growing incidence of anaphylaxis in adults, especially in the elderly population, is the primary factor driving the growth of the high dose segment. As epinephrine is considered as the first-line treatment for anaphylaxis, the increasing recommendation of high dose by healthcare professionals (HCP) across the globe for adult patients is fueling the growth of the segment. Moreover, market players are also focusing on providing generic, low-cost products, which are increasing the demand for affordable treatment options for managing anaphylactic reactions.

Several social and emotional factors contribute to the high prevalence of anaphylaxis in teenage and adult groups, including risk-taking behaviors with eating and disease denial. Adults with peanut allergy have more severe reactions than children. HCPs recommend a high as well as safe dose (usually 0.3 mg) of epinephrine auto-injectors to the patient group aged 12 years and above. Furthermore, anaphylaxis in the elderly population tends to be life-threatening and requires intensified medical intervention. Therefore, managing the high risk of anaphylaxis in this group, especially in elderly people, is expected to drive the uptake of epinephrine auto-injectors.

The burden of anaphylaxis among children is growing, hence it requires quick and effective management. Government and regulatory bodies are providing safeguards to prevent fatal reactions among children in the 6–12 years age group. Epinephrine through auto-injectors acts fast and can rapidly treat the most dangerous symptoms in children, including throat swelling, difficulty breathing, and low blood pressure. Thus, it is always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions due to anaphylaxis, thereby driving the segment growth.

In 2019, the below 6 years segment accounted for a 10% market share of the global epinephrine auto-injector market. Children in this age group are prescribed to be treated with 0.15 mg/0.1 mg dose capacity. An estimated 130% increase in emergency room visits for anaphylaxis among children aged 4 years old and younger reported between 2005 and 2014.  Since the management of anaphylaxis in this age group is becoming a major concern among HCPs and parents, vendors are focusing on introducing low-cost epinephrine auto-injectors for this age group.

The individual end-user segment accounted for the highest share in 2019. The segment is likely to grow with the highest growth rate mainly due to the growing demand for self-management of anaphylaxis. Individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. As the prevalence is growing rapidly worldwide, self-management is becoming increasingly important. Hence, the segment is likely to emerge as a major revenue generator during the forecast period.

HCPs in hospitals & clinics are using epinephrine auto-injectors for the emergency management of anaphylaxis. The market is growing at a healthy rate on account of the high adoption of these devices by emergency departments in hospitals and clinics. The availability of skilled HCPs with knowledge and expertise also attracts many patients to hospitals and clinics. Large and medium-sized hospitals are equipped with sophisticated healthcare infrastructure for emergency management of anaphylaxis. Hence, the share of this segment is likely to grow at a steady growth during the forecast period.

Market Segmentation by Dosage  

  • High
  • Low

Market Segmentation by Age Group

  • Below 6 Years
  • Between 6 & 12 years
  • Above 12 years

Market Segmentation by End-user   

  • Hospitals & Clinics
  • Individuals
  • Others

INSIGHTS BY GEOGRAPHY

North America dominates the epinephrine auto-injector market. The presence of a large disease population, coupled with better access to treatment for anaphylaxis, is the primary factor for its high market share. The strong presence of key vendors is also another reason for high product uptake in the region. Moreover, the rise in the anaphylactic patient pool and the launch of generic substitutes, which help to treat the condition effectively in adults and children groups, are likely to boost the growth during the forecast period.

Europe is the second-largest market. Better disease awareness, high healthcare spending, and the presence of key vendors are the primary factors for high market shares. Germany, France, the UK, Spain, and the Netherlands are the major revenue contributors to the region. The Europe market is likely to be driven by the increasing treatment-seeking population due to increased awareness of anaphylactic reactions.
Japan, Australia, and South Korea are the major revenue contributors in APAC for epinephrine auto-injectors. A low treatment-seeking population associated with social stigma in select regions, low awareness and comparatively minimal access to healthcare services, especially in developing countries are a few factors that limit growth potential in the region. However, the growth in disease prevalence, improvement in healthcare spending, increase in awareness for food allergies, including anaphylaxis, are expected to fuel the growth in the region.

Market Segmentation by Geography

  • Europe
    • Spain
    • Germany
    • Netherlands
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • Turkey
    • Israel
    • South Africa

INSIGHTS BY VENDORS

The global epinephrine auto-injector market is highly consolidated and is characterized by the presence of a few established vendors holding the majority of the market share. Vendors are offering several branded as well as generic epinephrine auto-injectors and are competing based on factors in terms of regulatory approvals, safety features, accurate dosing, convenience, technology, marketing strategies, and distribution channels.

Key Vendors

  • Mylan
  • Teva Pharmaceutical Industries
  • Amneal Pharmaceuticals

Other Vendors

  • Adamis Pharmaceuticals
  • ALK-Abelló
  • Bioprojet PHARMA
  • Bausch & Lomb
  • kaléo
  • Novartis

KEY MARKET INSIGHTS

  • The analysis of the epinephrine auto-injector market provides sizing and growth opportunities for the period 2019–2025.
  • Offers sizing and growth prospects of the market for the forecast period 2020–2025.
  • Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
  • Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
  • Delivers a complete overview of segments and the regional outlook of the market.
  • Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • ALK-Abelló
  • Amneal Pharmaceuticals
  • Bausch & Lomb
  • Bioprojet PHARMA
  • kaléo
  • MORE

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusion
4.1.2 Exclusion
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation by Dosage
4.4.2 Market Segmentation by Age Group
4.4.3 Market Segmentation by End-user
4.4.4 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance
7 Introduction
7.1 Anaphylaxis: Overview
7.1.1 Background
7.1.2 Epinephrine Auto-injectors for the Treatment of Anaphylaxis
7.2 Epinephrine Auto-injectors Market Snapshot

8 Market Opportunities & Trends
8.1 Emergence Of Innovative Solutions For Anaphylaxis Management
8.2 Vendors’ Growing Focus On Patient Assistance Programs
8.3 Increasing Demand For Generic Epinephrine Auto-Injectors At Pharma/Retail Stores

9 Market Growth Enablers
9.1 Rising Incidence Of Anaphylaxis
9.2 Growing Demand For Self-Administration Of Drugs
9.3 Availability Of Generic Versions Of Auto-Injectors

10 Market Restraints
10.1 Presence of Alternative Treatment Options
10.2 Adverse Side Effects Associated With Epinephrine Auto-Injectors
10.3 Shortage of Epinephrine Auto-Injectors
10.4 High Cost of Epinephrine Auto-Injectors

11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry

12 Dosage
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 High Dose
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Low Dose
12.4.1 Market Overview
12.4.2 Market Size & Forecast

13 Age Group
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Above 12 Years
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 6-12 Years
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Below 6 Years
13.5.1 Market Overview
13.5.2 Market Size & Forecast

14 End-User
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Individuals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Hospitals & Clinics
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Others
14.5.1 Market Overview
14.5.2 Market Size & Forecast

15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview

16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 North America: Dosage Segmentation
16.3.1 Market Snapshot & Growth Engine
16.4 Key Countries
16.4.1 US: MARKET SIZE & FORECAST
16.4.2 Canada: MARKET SIZE & FORECAST

17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Europe: Dosage Segmentation
17.3.1 Market Snapshot & Growth Engine
17.4 Key Countries
17.4.1 Germany: Market Size & Forecast
17.4.2 France: Market Size & Forecast
17.4.3 UK: Market Size & Forecast
17.4.4 Spain: Market Size & Forecast
17.4.5 Netherlands: Market Size & Forecast

18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 APAC: Dosage Segmentation
18.3.1 Market Snapshot & Growth Engine
18.4 Key Countries
18.4.1 Japan: Market Size & Forecast
18.4.2 Australia: Market Size & Forecast
18.4.3 South Korea: Market Size & Forecast

19 Middle-East & Africa
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Middle-East & Africa: Dosage Segmentation
19.3.1 Market Snapshot & Growth Engine
19.4 Key Countries
19.4.1 Israel: Market Size & Forecast
19.4.2 South Africa: Market Size & Forecast
19.4.3 Turkey: Market Size & Forecast

20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Latin America: Dosage Segmentation
20.3.1 Market Snapshot & Growth Engine
20.4 Key Countries
20.4.1 Brazil: Market Size & Forecast
20.4.2 Argentina: Market Size & Forecast

21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Mylan
21.2.2 Teva Pharmaceutical Industries
21.2.3 Amneal Pharmaceuticals
21.2.4 Adamis Pharmaceuticals
21.2.5 ALK-Abelló
21.2.6 Bausch & Lomb
21.2.7 BIOPROJET PHARMA
21.2.8 kaléo
21.2.9 Novartis

22 Key Company Profiles
22.1 Mylan
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Teva Pharmaceutical Industries
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Amneal Pharmaceuticals
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities

23 Other Prominent Vendors
23.1 Adamis Pharmaceuticals
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 ALK-Abelló
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities
23.3 BIOPROJET PHARMA
23.3.1 Business Overview
23.3.2 Product Offerings
23.3.3 Key Strategies
23.3.4 Key Strengths
23.3.5 Key Opportunities
23.4 Bausch & Lomb
23.4.1 Business Overview
23.4.2 Product Offerings
23.4.3 Key Strategies
23.4.4 Key Strengths
23.4.5 Key Opportunities
23.5 kaléo
23.5.1 Business Overview
23.5.2 Product Offerings
23.5.3 Key Strategies
23.5.4 Key Strengths
23.5.5 Key Opportunities
23.6 Novartis
23.6.1 Business Overview
23.6.2 Product Offerings
23.6.3 Key Strategies
23.6.4 Key Strengths
23.6.5 Key Opportunities

24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations

25 Quantitative Summary
25.1 Dosage
25.2 Age Group
25.3 End-User
25.4 Geography
25.5 North America: Dosage Segmentation
25.6 Europe: Dosage Segmentation
25.7 APAC: Dosage Segmentation
25.8 Middle East & Africa: Dosage Segmentation
25.9 Latin America: Dosage Segmentation

26 Appendix
26.1 Abbreviations
 
List of Exhibits
Exhibit 1 Segmentation of Global Epinephrine Auto-injectors Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Major Symptoms of Anaphylaxis
Exhibit 4 Most Common Triggers of Anaphylaxis
Exhibit 5 Conditions where Epinephrine Auto-injectors are Used for Children Include
Exhibit 6 Major Market Dynamics of Global Epinephrine Auto-injectors Market
Exhibit 7 Global Epinephrine Auto-injectors Market by Geography 2019 (%)
Exhibit 8 Global Epinephrine Auto-injectors Market by Dosage 2019 (%)
Exhibit 9 Impact of Emergence of Innovative Solutions for Anaphylaxis Management
Exhibit 10 Impact of Vendors’ Growing Focus on Patient Assistance Programs
Exhibit 11 Mylan’s Patient Assistance Program Snapshot
Exhibit 12 Impact of Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores
Exhibit 13 Impact of Rising Incidence of Anaphylaxis
Exhibit 14 Anaphylaxis Epidemiology 2000−2015
Exhibit 15 Hospital Admissions for All-cause Anaphylaxis (%)
Exhibit 16 Implications for Fatal Drug Anaphylaxis
Exhibit 17 Impact of Growing Demand for Self-administration of Drugs
Exhibit 18 Risk Factors to Consider Using Self-injectable Epinephrine
Exhibit 19 Impact of Availability of Generic Versions of Auto-injectors
Exhibit 20 Overview of Generic and Branded EpiPen Version
Exhibit 21 Impact of Presence of Alternative Treatment Options
Exhibit 22 Popular Alternative Methods for Anaphylaxis Treatment
Exhibit 23 Impact of Adverse Side Effects Associated with Epinephrine Auto-injectors
Exhibit 24 Common Side Effects of Epinephrine Auto-injectors
Exhibit 25 Some Rare Side-effects of Epinephrine
Exhibit 26 Adverse Effects of Epinephrine on Organs & Tissues
Exhibit 27 Impact of Shortage of Epinephrine Auto-injectors
Exhibit 28 Impact of High Cost of Epinephrine Auto-injectors
Exhibit 29 Average Price of Key Epinephrine Auto-injectors
Exhibit 30 Global Epinephrine Auto-injectors Market 2019–2025 ($ million)
Exhibit 31 Global Epinephrine Auto-injectors Market by Geography
Exhibit 32 Global Epinephrine Auto-injectors Market by Dosage
Exhibit 33 Global Epinephrine Auto-injectors Market by Age Group
Exhibit 34 Global Epinephrine Auto-injectors Market by End-user
Exhibit 35 Five Forces Analysis 2019
Exhibit 36 Incremental Growth by Dosage 2019 & 2025
Exhibit 37 Global Epinephrine Auto-injectors Market by Dosage
Exhibit 38 Global Epinephrine Auto-injectors Market by Dosage: Incremental Growth
Exhibit 39 Global Epinephrine Auto-injectors Market by Dosage: Absolute Growth
Exhibit 40 Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 41 Global Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 42 Global Epinephrine Auto-injectors Market by High Dose: Incremental and Absolute Growth
Exhibit 43 Usage of High Dose Epinephrine Auto-injectors
Exhibit 44 Global Epinephrine Auto-injectors Market by High Dose 2019–2025 ($ million)
Exhibit 45 Global Epinephrine Auto-injectors Market by Low Dose: Incremental & Absolute Growth
Exhibit 46 Usage of Low Dose Epinephrine Auto-injectors
Exhibit 47 Global Epinephrine Auto-injectors Market by Low Dose 2019–2025 ($ million)
Exhibit 48 Incremental Growth by Age Group 2019 & 2025
Exhibit 49 Global Epinephrine auto-injectors market by Age Group
Exhibit 50 Global Epinephrine Auto-injectors Market by Age Group: Incremental Growth
Exhibit 51 Global Epinephrine Auto-injectors Market by Age Group: Absolute Growth
Exhibit 52 Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)
Exhibit 53 Global Epinephrine Auto-injectors Market by Age Group 2019−2025 (%)
Exhibit 54 Global Epinephrine Auto-injectors Market for Above 12 Years: Incremental & Absolute Growth
Exhibit 55 Yearly Prevalence of Emergent Patients with Anaphylaxis by Age Group 2010−2014
Exhibit 56 Global Epinephrine Auto-injectors Market for Above 12 Years 2019–2025 ($ million)
Exhibit 57 Global Epinephrine Auto-injectors Market for 6−12 Years: Incremental & Absolute Growth
Exhibit 58 Action of a Standard Epinephrine Auto-injector
Exhibit 59 Global Epinephrine Auto-injectors Market for 6−12 Years 2019–2025 ($ million)
Exhibit 60 Global Epinephrine Auto-injectors Market for Below 6 Years: Incremental & Absolute Growth
Exhibit 61 Global Epinephrine Auto-injectors Market for Below 6 Years 2019–2025 ($ million)
Exhibit 62 Incremental Growth by End-user 2019 & 2025
Exhibit 63 Global Epinephrine Auto-injectors Market by End-user
Exhibit 64 Global Epinephrine Auto-injectors Market by End-user: Incremental Growth
Exhibit 65 Global Epinephrine Auto-injectors Market by End-user: Absolute Growth
Exhibit 66 Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)
Exhibit 67 Global Epinephrine Auto-injectors Market by End-user 2019−2025 (%)
Exhibit 68 Global Epinephrine Auto-injectors Market by Individuals: Incremental & Absolute Growth
Exhibit 69 Global Epinephrine Auto-injectors Market by Individuals 2019–2025 ($ million)
Exhibit 70 Global Epinephrine Auto-injectors Market by Hospitals & Clinics: Incremental & Absolute Growth
Exhibit 71 Global Epinephrine Auto-injectors Market by Hospitals & Clinics 2019–2025 ($ million)
Exhibit 72 Epinephrine Auto-injectors Market by Others: Incremental & Absolute Growth
Exhibit 73 Global Epinephrine Auto-injectors Market by Others 2019–2025 ($ million)
Exhibit 74 Incremental Growth by Geography 2019 & 2025
Exhibit 75 Global Epinephrine Auto-injectors Market by Geography
Exhibit 76 Global Epinephrine Auto-Injectors Market by Geography 2019: Key Countries ($ million)
Exhibit 77 Global Epinephrine Auto-Injectors Market by Geography: Incremental Growth
Exhibit 78 Global Epinephrine Auto-Injectors Market by Geography: Absolute Growth
Exhibit 79 Global Epinephrine Auto-Injectors Market by Geography 2019−2025 ($ million)
Exhibit 80 Global Epinephrine Auto-Injectors Market by Geography 2019−2025 (%)
Exhibit 81 Epinephrine Auto-Injectors Market in North America in 2019
Exhibit 82 North America Epinephrine Auto-injectors Market: Incremental & Absolute Growth
Exhibit 83 Epinephrine Auto-injectors Market in North America 2019–2025 ($ million)
Exhibit 84 Incremental Growth by Dosage 2019 & 2025
Exhibit 85 North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 86 North America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 87 Incremental Growth in North America 2019 & 2025
Exhibit 88 Epinephrine Auto-injectors Market in US 2019–2025 ($ million)
Exhibit 89 Epinephrine Auto-injectors Market in Canada 2019–2025 ($ million)
Exhibit 90 Epinephrine Auto-injectors Market in Europe 2019
Exhibit 91 Europe Epinephrine Auto-injectors Market: Incremental & Absolute Growth
Exhibit 92 Epinephrine Auto-injectors Market in Europe 2019–2025 ($ million)
Exhibit 93 Incremental Growth by Dosage 2019 & 2025
Exhibit 94 Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 95 Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 96 Incremental Growth in Europe 2019 & 2025
Exhibit 97 Knowledge Distribution about Emergency Kit for Managing Anaphylaxis among Teachers and Child-care Providers in Germany
Exhibit 98 Epinephrine Auto-injectors Market in Germany 2019–2025 ($ million)
Exhibit 99 Epinephrine Auto-injectors Market in France 2019–2025 ($ million)
Exhibit 100 Epinephrine Auto-injectors Market in UK 2019–2025 ($ million)
Exhibit 101 Epinephrine Auto-injectors Market in Spain 2019–2025 ($ million)
Exhibit 102 Epinephrine Auto-injectors Market in Netherlands 2019–2025 ($ million)
Exhibit 103 APAC Epinephrine Auto-injectors Market: Incremental & Absolute Growth
Exhibit 104 Epinephrine Auto-injectors Market in APAC 2019 ($ million)
Exhibit 105 Epinephrine Auto-injectors Market in APAC 2019–2025 ($ million)
Exhibit 106 APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 107 APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 108 Incremental Growth in APAC 2019 & 2025
Exhibit 109 Epinephrine Auto-injectors Market in Japan 2019–2025 ($ million)
Exhibit 110 Epinephrine Auto-injectors Market in Australia 2019–2025 ($ million)
Exhibit 111 Epinephrine Auto-injectors Market in South Korea 2019–2025 ($ million)
Exhibit 112 Epinephrine Auto-injectors Market in Middle East & Africa 2019 ($ million)
Exhibit 113 Middle East & Africa Epinephrine Auto-injectors Market: Incremental & Absolute Growth
Exhibit 114 Epinephrine Auto-injectors Market in Middle East & Africa 2019–2025 ($ million)
Exhibit 115 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 116 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 117 Incremental Growth in Middle East & Africa 2019 & 2025
Exhibit 118 Epinephrine Auto-injectors Market in Israel 2019–2025 ($ million)
Exhibit 119 Epinephrine Auto-injectors Market in South Africa 2019–2025 ($ million)
Exhibit 120 Epinephrine Auto-injectors Market in Turkey 2019–2025 ($ million)
Exhibit 121 Epinephrine Auto-injectors Market in Latin America 2019 ($ million)
Exhibit 122 Latin America Epinephrine Auto-injectors Market: Incremental & Absolute Growth
Exhibit 123 Epinephrine Auto-injectors Market in Latin America 2019–2025 ($ million)
Exhibit 124 Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Exhibit 125 Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Exhibit 126 Incremental Growth in Latin America 2019 & 2025
Exhibit 127 Epinephrine Auto-injectors Market in Brazil 2019–2025 ($ million)
Exhibit 128 Epinephrine Auto-injectors Market in Argentina 2019–2025 ($ million)
Exhibit 129 Global Epinephrine Auto-injectors Market: Vendors Market Share (2019)
Exhibit 130 Mylan: Sales by Geography 2019 (%)
Exhibit 131 Teva Pharmaceutical Industries: Revenue by Segment 2017 & 2018 ($ million)
Exhibit 132 Adamis Pharmaceuticals: R&D Expenditure 2016−2018 ($ million)
Exhibit 133 ALK-Abelló: Revenue by Product Line 2017 & 2018 ($ million)
Exhibit 134 ALK-Abelló: Revenue by Geography 2018 ($ million)
Exhibit 135 Novartis: R&D Expenditure 2016−2018 ($ million)
Exhibit 136 Novartis: Revenue by Segment 2017 & 2018 ($ million)
 
List Of Tables
Table 1  Key Caveats
Table 2  Currency Conversion 2013−2019
Table 3  Anaphylaxis Definitions Worldwide
Table 4  Major Epinephrine Auto-injectors Under Development
Table 5  Popular Patient Assistance Programs Offered by Vendors
Table 6  Potential Advantages of Intravenous Epinephrine Delivery for Anaphylaxis Treatment
Table 7  Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 8  Significant Players Offering High Dose Epinephrine Auto-injectors
Table 9  Significant Players Offering Low Dose Epinephrine Auto-injectors
Table 10 Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)
Table 11 Significant Players Offering Epinephrine Auto-injectors for Patients Above 12 Years
Table 12 Significant Players Offering Epinephrine Auto-injectors for Patients in the Age Group of 6−12 Years
Table 13 Significant Players Offering Epinephrine Auto-injectors for Below 6 Years Patient Group
Table 14 Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)
Table 15 Global Epinephrine Auto-injectors Market by Geography 2019−2025 ($ million)
Table 16 North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 17 Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 18 Incremental Growth by Dosage 2019 & 2025
Table 19 APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 20 Incremental Growth by Dosage 2019 & 2025
Table 21 Middle East & Africa Epinephrine Auto-injectors market by Dosage 2019−2025 ($ million)
Table 22 Incremental Growth by Dosage 2019 & 2025
Table 23 Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 24 Competitive Structure Analysis of Global Epinephrine Auto-injectors Market 2019
Table 25 Global Epinephrine Auto-injectors Market: Vendor Ranking 2019
Table 26 Mylan: Major Product Offerings
Table 27 Teva Pharmaceutical Industries: Major Product Offerings
Table 28 Amneal Pharmaceuticals: Major Product Offerings
Table 29 Adamis Pharmaceuticals: Major Product Offerings
Table 30 ALK-Abelló: Major Product Offerings
Table 31 BIOPROJET PHARMAl: Major Product Offerings
Table 32 Bausch & Lomb: Major Product Offerings
Table 33 kaléo: Major Product Offerings
Table 34 Novartis: Major Product Offerings
Table 35 Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 36 Global Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Table 37 Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)
Table 38 Global Epinephrine Auto-injectors Market by Age Group 2019−2025 (%)
Table 39 Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)
Table 40 Global Epinephrine Auto-injectors Market by End-user 2019−2025 (%)
Table 41 Global Epinephrine Auto-injectors Market by Geography 2019−2025 ($ million)
Table 42 Global Epinephrine Auto-injectors Market by Geography 2019−2025 (%)
Table 43 North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 44 North America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Table 45 Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 46 Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Table 47 APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 48 APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Table 49 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 50 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)
Table 51 Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)
Table 52 Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ALK-Abelló
  • Adamis Pharmaceuticals
  • Amneal Pharmaceuticals
  • Bausch & Lomb
  • Bioprojet PHARMA
  • Mylan
  • Novartis
  • Teva Pharmaceutical Industries
  • kaléo
Note: Product cover images may vary from those shown
5 of 5

Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...

Adroll
adroll